14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DYN vs MESO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Dyne Therapeutics, Inc. (DYN) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). DYN carries a Unified Composite Score of 47.5/100 (HOLD) at $16.68 (N/M Forward P/E, 0.0% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin).
Growth vs. Quality Trade-Off: DYN earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. MESO 35.5/100 SELL) and 1.73β · 59% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: DYN is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 45.9); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DYN vs MESO. Trailing 12-month operating profitability (DYN 0.0% vs MESO -42.6%) and valuation multiples (DYN N/M vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DYN vs MESO Key Questions & Quantitative Answers
As of Nov 16, 2026, Dyne Therapeutics, Inc. (DYN) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). DYN carries a Unified Composite Score of 47.5/100 (HOLD) at $16.68 (N/M Forward P/E, 0.0% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin). Growth vs. Quality Trade-Off: DYN earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. MESO 35.5/100 SELL) and 1.73β · 59% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DYN is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 45.9); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MESO leads the Growth & Scale pillar: DYN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, DYN generates N/A in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, DYN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.
DYN and MESO trade at balanced relative valuation multiples. DYN trades at N/M Forward P/E, N/M Trailing P/E, 0.19x PEG, and N/M EV/Revenue (unreported FCF margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DYN (-74.6% ROE) versus MESO (-9.9% ROE) capital efficiency.
In options market volatility and institutional positioning, DYN carries 124.9% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.73β · 59% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.